

Sionna Therapeutics topline clinical data for cystic fibrosis programs disappoints, opting to discontinue its SION-719 candidate.
You can purchase shares of Sionna Therapeutics (NASDAQ:SION) through any online brokerage.
Other companies in Sionna Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Sionna Therapeutics has a consensus price target of $44.25.
The stock price for Sionna Therapeutics (NASDAQ: SION) is $3.58 last updated November 10, 2026 at 7:59 AM EST.
There are no upcoming dividends for Sionna Therapeutics.
Sionna Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Sionna Therapeutics.
Sionna Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis...